Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome

https://doi.org/10.1016/0091-3057(82)90340-9Get rights and content

Abstract

The effects of the alpha-2 adrenergic agonist, clonidine, on the “quasi-morphine withdrawal syndrome” (QMWS) were examined in drug naive rats. The QMWS was induced by combined systemic administration of iso-butyl-methylxanthine (IBMX: 15 mg/kg, IP) and naloxone (1 mg/kg, IP). Pretreatment with clonidine (50 μg/kg, IP) significantly decreased the incidence of 11 out of 16 withdrawal signs. Since clonidine suppresses signs and symptoms of true morphine withdrawal, the suppression of methylxanthine effects demonstrates an additional similarity of the QMWS to true morphine withdrawal. These ressults suggest that a significant common neural mechanism of both the QMWS and true morphine withdrawal is affected by clonidine.

References (26)

  • F.E. Bloom et al.

    Beta-endorphin: cellular localization, electrophysiological and behavioral effects

    Adv. Biochem. Psychopharmac.

    (1978)
  • D.S. Charney et al.

    Clonidine effects on cardiovascular function, specific signs and symptoms during abrupt withdrawal from methadone

    Archs gen. Psychiat.

    (1981)
  • H.O.J. Collier et al.

    Quasi-morphine abstinence syndrome

    Nature

    (1974)
  • Cited by (0)

    View full text